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KEY POINTS 17 
Question: What is the association of gestational weight gain, across a range of pre-pregnancy weights, 18 
with maternal and infant outcomes?  19 
Findings: In this meta-analysis of individual participant data from 25 pooled cohort studies and 196670 20 
participants, pre-pregnancy weight and the magnitude of gestational weight gain were associated with risk 21 
of adverse outcomes (defined as pre-eclampsia, gestational hypertension, gestational diabetes, caesarean 22 
section, preterm birth, and small or large size-for-gestational-age at birth), although the magnitude of 23 
weight gain was weakly associated with the adverse outcomes assessed.  24 
Meaning: These findings may inform prenatal counseling regarding optimal weight gain during 25 
pregnancy, although the magnitude of weight gain was weakly associated with the outcomes assessed.  26 
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ABSTRACT 27 
Importance: Both low and high gestational weight gain have been associated with adverse maternal and 28 
infant outcomes, but optimal gestational weight gain ranges remain uncertain and not well defined for all 29 
pre-pregnancy weights.  30 
Objective: To examine the association of ranges of gestational weight gain with risks of adverse maternal 31 
and infant outcomes and to estimate optimal gestational weight gain ranges across a range of pre-32 
pregnancy weights.  33 
Design, Setting, and Participants: Individual participant data meta-analysis using data from 196670 34 
participants from 25 cohort studies from Europe and North-America (main study-sample). Optimal 35 
gestational weight gain ranges were estimated for each pre-pregnancy BMI category by selecting the 36 
range of gestational weight gain that was associated with lower risk for the main endpoint, defined as ‘any 37 
adverse outcome’. Individual participant data from 3505 participants from 4 separate hospital-based 38 
cohorts were used as validation sample. Data were collected between 1989 and 2015. Final date of 39 
follow-up was December 2015. 40 
Exposures: Gestational weight gain. 41 
Main Outcomes and Measures: ‘Any adverse outcome’, defined as the presence of one or more of the 42 
following outcomes: pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, 43 
preterm birth, small or large size-for-gestational-age at birth. 44 
Results: Of the 196670 women included in the main sample, 7809 (4.0%), 133788 (68.0%), 38828 45 
(19.7%), 11992 (6.1%), 3284 (1.7%) and 969 (0.5%) were underweight, normal weight, overweight, 46 
obesity grade 1, obesity grade 2 and obesity grade 3 at baseline, respectively. Overall, any adverse 47 
outcome occurred in 37.2% (n=73161) of women, ranging from 34.7% (n=2706) in women with 48 
underweight to 61.1% (n=592) in women with obesity grade 3. Optimal weight gain ranges were 14.0-49 
<16.0 kg for underweight, 10.0-<18.0 kg for normal weight, 2.0-<16.0 kg for overweight, 2.0-<6.0 kg for 50 
obesity grade 1, weight loss- weight gain of <4.0 kg for obesity grade 2, and 0.0-<6.0 kg for obesity grade 51 
3. These ranges were associated with low to moderate discrimination between those with and without 52 
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adverse outcomes (Areas-under-the-curve (AUCs): 0.546-0.759). Results for discriminative performance 53 
in the validation sample were similar to corresponding results in the main study-sample (AUCs: 0.506-54 
0.787). 55 
Conclusions and Relevance: In this meta-analysis of pooled individual participant data from 25 cohort 56 
studies, the risk of adverse maternal and infant outcomes varied by gestational weight gain and across the 57 
range of pre-pregnancy weights. The estimates of optimal gestational weight gain may inform prenatal 58 
counseling, although the optimal weight gain ranges had limited predictive value for the outcomes 59 
assessed.  60 
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INTRODUCTION 61 
Gestational weight gain has been related to the risks of pregnancy complications, maternal postpartum 62 
weight retention and offspring obesity.
1-3 
Gestational weight gain reflects multiple characteristics, 63 
including maternal fat accumulation, fluid expansion, and growth of the fetus, placenta and uterus.
4
 64 
Gestational weight gain is necessary to ensure a healthy fetus, but excessive gestational weight gain has 65 
been associated with adverse outcomes. Higher pre-pregnancy body mass index (BMI) has also been 66 
associated with lower gestational weight gain, as well as with increased risks of adverse maternal and 67 
infant outcomes. Therefore, optimal gestational weight gain ranges need to account for pre-pregnancy 68 
BMI.
5,6
 Existing guidelines for gestational weight gain by the US Institute of Medicine (IOM) have 69 
limitations including reliance on a limited number of observational studies relating gestational weight 70 
gain to five maternal and offspring outcomes and insufficient information about important pregnancy 71 
outcomes, including gestational hypertension and gestational diabetes.
7
 In addition, these guidelines do 72 
not include recommendations for obesity grades 1 to 3 separately, even though the prevalence of extreme 73 
obesity is rising in Western populations. Information regarding optimal gestational weight gain across a 74 
range of maternal BMI categories is important for identification of groups at increased risk in obstetric 75 
care.  76 
 This study pooled individual participant data from 25 pregnancy and birth cohorts from Europe 77 
and North-America to assess the associations of the amount of weight gain with maternal and infant 78 
outcomes according to baseline weight status of underweight, normal weight, overweight, obesity grade 79 
1, obesity grade 2 and obesity grade 3.  80 
 81 
METHODS 82 
 83 
Inclusion criteria and participating cohorts 84 
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This study was part of an international LifeCycle Project collaboration on Maternal Obesity and 85 
Childhood Outcomes (MOCO).
8,9 
Pregnancy and birth cohort studies were eligible for inclusion if they 86 
included mothers with singleton live-born children born between 1989 and 2015, had information on 87 
maternal pre- or early-pregnancy BMI and had at least one offspring measurement (birth weight or 88 
childhood BMI). No exclusions were made based on previous pregnancy- or birth complications. Cohorts 89 
included were approved by their local institutional review boards and written informed consent was 90 
obtained from participants. We invited 50 Western cohorts from Europe, North America and Oceania, 91 
selected from existing collaborations on childhood health (EarlyNutrition Project, CHICOS Project, 92 
www.birthcohorts.net assessed until July 2014), of which 39 agreed to participate. Only participants with 93 
information on maternal pre-pregnancy BMI, gestational weight gain and at least one maternal or infant 94 
outcome of interest were included (n=200175 participants from 29 cohorts). Of the 29 cohorts with 95 
required data, 25 (n=196670) were population-based and were included as  main study sample. The 96 
remaining 4 cohorts were hospital-based, and were included as external validation sample (n=3505, 97 
eFigure 1). eTable 1 lists included cohorts with their data collection methods. Women could be included 98 
more than once in the analyses if they had multiple singleton pregnancies during the study period of a 99 
specific cohort. Anonymized datasets were stored on a single central secured data server with access for 100 
the main analysts (EV, RG).  101 
 102 
Maternal pre-pregnancy BMI and gestational weight gain 103 
Maternal pre-pregnancy BMI (kg/m
2
) was grouped into categories of 2 kg/m
2
 and into clinical BMI 104 
groups according to World Health Organization (WHO) definitions.
10
 Data on total gestational weight 105 
gain (kg), defined as the difference between the latest weight before delivery and pre-pregnancy weight, 106 
was provided by cohorts. Gestational weight gain was grouped into categories of 2 kg each, ranging from 107 
weight loss to weight gain of ≥28 kg. Smaller increments of gestational weight gain were not used 108 
because of insufficient statistical power among underweight and severely obese women. Categories at the 109 
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extremes of gestational weight gain were combined for maternal underweight, obesity grade 2, and 110 
obesity grade 3. All women had information on maternal pre-pregnancy BMI, total gestational weight 111 
gain and presence or absence of an adverse outcome (defined below). 112 
 113 
Maternal and infant adverse outcomes 114 
Adverse outcomes were pre-eclampsia, gestational hypertension, gestational diabetes, preterm birth, small 115 
size-for-gestational-age at birth, large size-for-gestational-age at birth, and caesarean section. Preterm 116 
birth was defined as gestational age at birth <37 weeks. Sex- and gestational age-adjusted standard-117 
deviation (SD) scores for birth weight were calculated using a North-European reference chart.
11
 Small 118 
and large size-for-gestational-age at birth were defined as sex- and gestational-age-adjusted birth weight 119 
<10
th
 percentile and >90
th
 percentile, respectively, within each cohort. The main outcome of analyses was 120 
the composite ‘any adverse outcome’, defined as the presence of at least one of the outcomes described 121 
above.  122 
 For sensitivity analyses, sex- and age-adjusted SD scores were calculated for childhood BMI 123 
based on WHO reference growth charts.
12,13
 SD scores were obtained using data from the highest age 124 
available for each child (median age (Q1, Q3): 84.9 months (61.9, 95.9)) and categorized into 125 
underweight, normal weight, or overweight/obesity (referred to as overweight) using WHO cut-offs.
 12,13 
 126 
 127 
Statistical analysis 128 
First, we used exploratory multilevel linear regression models to assess associations of maternal baseline 129 
characteristics with total gestational weight gain. Second, we estimated the absolute risks of any adverse 130 
outcome across the full range of maternal pre-pregnancy BMI and gestational weight gain. Absolute risks 131 
were calculated as  percentage of women with any adverse outcome within each combination of BMI and 132 
gestational weight gain categories. Similarly, we estimated the absolute risks of any adverse outcome and 133 
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each individual outcome across the range of gestational weight gain categories, within each clinical BMI 134 
group. Third, we constructed ranges of optimal weight gain per clinical BMI group. We calculated the 135 
Odds Ratios (ORs) of any adverse outcome for each gestational weight gain category within a clinical 136 
BMI group, as compared to all other mothers within that BMI group. We analysed individual level data 137 
from all cohorts simultaneously using multilevel models. Our models followed a two-level hierarchical 138 
structure with participants (level 1) nested within cohorts (level 2). We used generalized linear mixed 139 
model with a binominal distribution and logit link. We included a random intercept at cohort level to 140 
allow variation in the baseline risk of each cohort. Allowing a random slope for gestational weight gain 141 
did not improve the models. Model assumptions regarding linearity, independent errors and influential 142 
values were met. We defined optimal gestational weight gain as all weight gain categories with a 143 
statistically significant protective association (OR below one) for any adverse outcome.
14
 If a weight gain 144 
category with a non-significant association was between two significant estimates with an OR below one, 145 
that category was included in the optimal weight gain range. To construct easily interpretable optimal 146 
weight gain ranges applicable for clinical practice, these main analyses were not adjusted for maternal age 147 
or parity. We also assessed continuous associations of maternal pre-pregnancy BMI and total gestational 148 
weight gain in SDS with any adverse outcome and compared the strength of these associations by testing 149 
the difference in ORs. We performed six sensitivity analyses: 1) We re-defined the gestational weight 150 
gain ranges based on protective associations (OR below one) only, regardless of statistical significance; 2) 151 
As gestational weight gain depends on length of gestation, we adjusted the models for gestational age at 152 
birth and performed a sensitivity analysis excluding pre-term births; 3) A sensitivity analysis was 153 
performed excluding participants with missing data on separate adverse maternal and infant outcomes.; 4) 154 
To explore whether optimal ranges would change when maternal age and parity were taken into account, 155 
we performed a sensitivity analysis adjusting for maternal age and parity. 5) To explore whether optimal 156 
ranges would change depending on the definition of the composite outcome, we performed additional 157 
analyses excluding caesarean section as an adverse outcome and additional analyses including childhood 158 
underweight and overweight as adverse outcomes; 6) To address possible reverse causation, we 159 
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performed analyses excluding pre-eclampsia and gestational diabetes as outcomes. We also constructed 160 
optimal gestational weight gain ranges for weight gain in the first half of pregnancy, defined as the 161 
difference between weight at median gestational age of 15.4 weeks (Q1, Q3: 13.2, 17.1) and pre-162 
pregnancy weight, using a similar approach.  163 
 Next, as secondary analyses, we assessed the clinical performance of the ranges of this study, 164 
compared to the IOM classification, by assessing the number of participants classified as having 165 
inadequate or excessive weight gain, the associations with adverse outcomes using binary logistic 166 
multilevel models and the discriminative performance for both classifications. We assessed the 167 
discriminative performance of the classification from this study and the IOM, which is the ability of the 168 
classification to discriminate between those with and without the outcome, based on areas under the 169 
Receiver Operator Characteristic curve (AUC).
15
 We obtained predicted probabilities from binary logistic 170 
multilevel models assessing the associations of inadequate and excessive gestational weight gain with the 171 
outcomes. These predicted probabilities were used to calculate Receiver Operator Characteristic (ROC) 172 
curves and AUC. To assess the associations of the optimal weight gain ranges with clinically relevant 173 
outcomes not used for the construction of the ranges, we also assessed the associations of the optimal 174 
weight gain ranges with low and high birth weight (≤2,500 g or ≥4,000 g). Last, we assessed the clinical 175 
performance of both classifications in the external validation sample (n=3505). All statistical tests were 2-176 
sided, with a significance threshold of 0.05. However, the secondary analyses were not adjusted for 177 
multiple testing, and therefore these findings should be considered exploratory. Statistical analyses were 178 
performed using the Statistical Package of Social Sciences version 24.0 for Windows (SPSS Inc, Chicago, 179 
IL, USA) and R statistical software version 3.3.3.  180 
 181 
RESULTS 182 
10 
 
Participant’s characteristics 183 
196670 women were included in the main sample (median age (Q1, Q3): 30.0 years (27.0, 33.0)), 40937 184 
(90.1%) European/White) (Table 1). 7809 (4.0%), 133788 (68.0%), 38828 (19.7%), 11992 (6.1%), 3284 185 
(1.7%) and 969 (0.5%) had underweight, normal weight, overweight, obesity grade 1, obesity grade 2 and 186 
obesity grade 3, respectively. Overall, any adverse outcome occurred in 37.2% (n=73161) of women, 187 
ranging from 34.7% (n=2706) in women with underweight to 61.1% (n=592) in women with obesity 188 
grade 3. Women who gained more gestational weight had a lower maternal pre-pregnancy BMI, were 189 
slightly younger and nulliparous, as compared to multiparous women (eTable 2). 169437 women (86.2%) 190 
had no missing data for any individual adverse outcome. Of the remainder, 17093 (8.7%) were missing 191 
information on gestational hypertensive disorders (including pre-eclampsia and gestational hypertension), 192 
6898 (3.5%) on gestational diabetes, 9786 (5.0%) on caesarean section, 8541 (4.3%) on preterm birth and 193 
6453 (3.3%) on size-for-gestational age at birth (eTable 3).  194 
 Within the validation sample, 3505 women were included (median age (Q1, Q3): 31.0 years 195 
(27.7, 34.7)), 1696 (99.2%) European/White) of whom 277 (7.9%), 2400 (68.5%), 577 (16.5%), 188 196 
(5.4%), 53 (1.5%), and 10 (0.3%) had underweight, normal weight, overweight, obesity grade 1, obesity 197 
grade 2 and obesity grade 3, respectively. Any adverse outcome occurred in 1423 (40.6%) of all women 198 
(eTable 4). 3059 (87.3%) had no missing data for any individual adverse maternal and infant outcomes. 199 
Of the remainder, 423 (12.1%) were missing data on gestational hypertensive disorders, 421 (12.0%) on 200 
gestational diabetes, 15 (0.4%) on caesarean section, 426 (11.9%) on preterm birth and 7 (0.2%) on size-201 
for-gestational age at birth (eTable 3). eTables 5 and 6 give cohort-specific information. Based on the 202 
cohort profiles of all included cohorts, the percentage of women included with multiple singleton 203 
pregnancies is about 1%. 204 
 205 
Maternal pre-pregnancy BMI, gestational weight gain and absolute risks of adverse outcomes 206 
The absolute risks of any adverse outcome increased across the full range of maternal pre-pregnancy BMI 207 
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and were largely independent of gestational weight gain (Figure 1). The lowest absolute risks were 208 
observed among women with low to normal
 
BMI and a moderate to high total gestational weight gain. 209 
The lowest risk was 26.7% (ncases/ntotal=16/60) for women with a BMI <18.0 kg/m
2 
and gestational weight 210 
gain of 26.0-27.9 kg. The highest absolute risks were observed among women with a high BMI and a 211 
high gestational weight gain. The highest risk was 94.4% (ncases/ntotal=17/18) for women with a BMI ≥40.0 212 
kg/m
2 
and gestational weight gain of 20.0-21.9 kg. Among underweight women, the absolute risk of any 213 
adverse outcome ranged from 29.2% (ncases/total=387/1326) for weight gain of 14.0-15.9 kg to 50.2% 214 
(ncases/total =203/404) for weight gain of <8.0 kg (Figure 2). Of all outcomes separately, the absolute risk 215 
was highest for small size-for-gestational-age (highest risk: 32.1% (ncases/total=125/390) for weight gain of 216 
<8 kg). Among normal weight women, the absolute risk of any adverse outcome ranged from 31.7% 217 
(ncases/total =7314/23073) for weight gain of 14.0-15.9 kg to 46.9%( ncases/total =1256/2679) for weight gain 218 
≥28.0 kg and was highest at both extremes of gestational weight gain. Among women with overweight, 219 
the absolute risk of any adverse outcome increased from 37.3% (ncases/total =249/667) for weight gain of 220 
2.0-3.9 kg to 56.4% (ncases/total =624/1107) for weight gain of ≥28.0 kg, with the highest risk for caesarean 221 
section (highest risk: 25.1% (ncases/total=272/1084) for weight gain of ≥28.0 kg). Among women with 222 
obesity grades 1 to 3, the absolute risk of any adverse outcome increased over the range of gestational 223 
weight gain. The highest absolute risks were 63.7% (ncases/total =160/251) for weight gain of ≥28.0 kg in 224 
women with obesity grade 1, 67.7% (ncases/total =384/567) weight gain of ≥16.0 kg in women with obesity 225 
grade 2 and 78.8% (ncases/total =93/118) for weight gain of ≥16.0 kg in women with obesity grade 3. The 226 
association of maternal pre-pregnancy BMI with the risk of any adverse outcomes was stronger than the 227 
association of gestational weight gain (p-value for comparison <0.001). Absolute data for each gestational 228 
weight gain category are shown in eTable 7. 229 
 230 
Optimal gestational weight gain per clinical BMI group 231 
Optimal gestational weight gain ranges are shown in Figure 3. Odds Ratios (ORs) and Absolute Risk 232 
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Reductions (ARRs) for each weight gain category were 14.0-<16.0 kg for underweight women (Odds 233 
Ratio (OR) 0.74 (95% CI: 0.65, 0.84), Absolute Risk Reduction (ARR): 0.07 (95% CI:0.04, 0.09)), 10.0-234 
<18.0 kg for normal weight women (ORs at the outer ends of this range: 0.96 (95% CI: 0.93, 0.99), 0.91 235 
(95% CI: 0.88, 0.95), ARRs: 0.01 (95% CI: 0.00, 0.01), 0.02 (95 % CI: 0.01, 0.03)), 2.0-<16.0 kg for 236 
overweight women (ORs at the outer ends of this range: 0.81 (95% CI: 0.69, 0.95) 0.90 (95% CI: 0.85, 237 
0.96), ARRs: 0.05 (95% CI: 0.01, 0.08), 0.02 (95% CI: 0.01, 0.04)), 2.0-<6.0 kg for obesity grade 1 (ORs 238 
at the outer ends of this range: 0.76 (95% CI: 0.64, 0.91), 0.73 (95% CI: 0.64, 0.84), ARRs: 0.07 (95% 239 
CI: 0.02, 0.11), 0.08 (95% CI: 0.04, 0.11)), weight loss-weight gain of <4.0 kg for obesity grade 2 240 
(median weight loss in this category: -3.0 kg) (ORs at the outer ends of this range: 0.55 (95% CI: 0.39, 241 
0.78), 0.67 (95% CI: 0.51, 0.88),ARRs: 0.14 (95% CI: 0.06, 0.22), 0.10 (95% CI: 0.03, 0.17)) and 0.0-242 
<6.0 kg for obesity grade 3 (ORs at the outer ends of this range: 0.59 (95% CI: 0.41, 0.85), 0.62 (95% CI: 243 
0.41, 0.94), ARRs: 0.12 (95% CI: 0.03, 0.21), 0.10 (95% CI: 0.00, 0.20)) (ORs and ARRs for each weight 244 
gain category used to determine the optimal ranges are given in eTable 8 and eTable 9, respectively). 245 
eTable 10 describes the ranges defined in this study and the IOM ranges. Ranges in this study were 246 
roughly comparable to IOM ranges for underweight, normal weight and overweight, and lower for all 247 
obesity grades. This study classified 11.3% (n=22236) and 33.8% (n=66463) of women in the main 248 
sample with inadequate and excessive weight gain, respectively. The IOM categories classified 21.5% 249 
(n=42323) and 42.0% (n=82544) with inadequate and excessive gestational weight gain. Gestational 250 
weight gain outside the ranges from the current study and IOM was associated with adverse outcomes 251 
(eFigure 2, eFigure 3). Each classification system had a low to moderate ability to distinguish between 252 
those with and without adverse outcomes (Areas-under-the-curve (AUCs): 0.546-0.772) (eFigure 4).  253 
 254 
Sensitivity analyses 255 
Sensitivity analyses, in which optimal gestational weight gain was determined based on protective 256 
associations, regardless of statistical significance, resulted in broader ranges of optimal weight gain 257 
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(eFigure 5). Similar optimal weight gain ranges were observed when length of gestation was considered 258 
and when participants with missing individual outcome data were excluded. Sensitivity analyses showed 259 
that optimal weight gain definitions were not influenced by including or excluding preterm birth, 260 
caesarean section, childhood underweight and overweight, gestational diabetes and pre-eclampsia as 261 
adverse outcomes or by adjusting for maternal age and parity (eTable 11). eFigure 6, eTable 12 and 262 
eTable 13 in Supplement show that, 84.6% of participants classified with excessive weight gain in the 263 
full pregnancy, would also be classified with excessive weight gain in the first half of pregnancy. Results 264 
for the validation sample showed that the discriminative performance of the optimal weight gain 265 
definitions developed in this study and weight gain classified according to the IOM guidelines were 266 
consistent with findings in the main study sample (AUCs: 0.501-0.788) (eTable 14, eFigure 7 , eFigure 267 
8).  268 
 269 
DISCUSSION 270 
Maternal pre-pregnancy BMI, and to a lesser extent gestational weight gain, are associated with rates of 271 
adverse maternal and infant adverse outcomes. Weight gain ranges that were associated with lower rates 272 
of adverse outcomes were 14.0-<16.0 kg for underweight, 10.0-<18.0 kg for normal weight, 2.0-<16.0 kg 273 
for overweight, 2.0-<6.0 kg for obesity grade 1, weight loss- weight gain of <4.0 kg for obesity grade 2, 274 
and 0.0-<6.0 kg for obesity grade 3. Gestational weight gain outside these ranges was associated with 275 
adverse outcomes. However, discriminative performance of gestational weight gain with adverse maternal 276 
and infant outcomes was low to moderate. Pre-pregnancy BMI was more strongly associated with adverse 277 
maternal and infant outcomes. 278 
  
Pre-pregnancy BMI is significantly associated with pregnancy complications and offspring 279 
obesity and is also associated with gestational weight gain
5,6
. Results from this study suggest that 280 
maternal pre-pregnancy BMI was more strongly associated with adverse maternal and infant outcomes 281 
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and may be an important focus for preconception counseling. Associations of categories of gestational 282 
weight gain with adverse outcomes were relatively small. Importantly, associations of women with a pre-283 
pregnancy BMI higher than 36 kg/m
2
 and gestational weight gain of more than 20 kg with any adverse 284 
outcome approached 95%.  285 
 Previous studies attempting to define optimal gestational weight gain associated with fewer 286 
adverse outcomes differed considerably in study populations, statistical approaches, outcomes, and 287 
conclusions regarding optimal gestational weight gain ranges.
14,16-22
 Despite these methodological 288 
challenges, five of these studies were included for construction of current IOM guidelines. IOM 289 
guidelines are limited by their non-systematic approach, lack of inclusion of maternal pregnancy 290 
complications, and lack of consideration of pre-pregnancy obesity severity.
7,21
 Only one previous study of 291 
120,251 obese US women defined optimal weight gain ranges according to maternal obesity grade 1 (4.5-292 
11.3 kg), obesity grade 2 (0-4.1 kg) and obesity grade 3 (<4 kg weight loss), and this study used data from 293 
term births only.
21
 The present study focused on common and important adverse maternal and infant 294 
outcomes, included women from multiple Western countries, and compared the associations of 295 
gestational weight gain with associations of pre-pregnancy BMI with adverse outcomes. Consistent with 296 
IOM guidelines, this study used total gestational weight gain to identify optimal gestational weight gain 297 
ranges instead of gestational weight gain per week, since gestational weight gain does not have a linear 298 
pattern .
7,8 
Total gestational weight gain is dependent on pregnancy duration. The observed results were 299 
similar after adjustment for gestational age at birth and after excluding preterm births. Consistent with 300 
IOM guidelines, this study showed that among women with higher pre-pregnancy BMI, lower gestational 301 
weight gain was associated with fewer adverse outcomes. Gestational weight gain ranges for women with 302 
obesity grades 1 to 3 were lower than IOM guidelines and even involved weight loss for severely obese 303 
women, although neither classifications were predictive for adverse outcomes. However, results for 304 
severely obese women should be interpreted with caution, as optimal gestational weight gain ranges for 305 
obesity grades 1-3 associated with better outcomes fluctuate and do not follow a clear linear trend. These 306 
results may represent the relatively small sample size of women with obesity and lack of statistical power, 307 
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rather than biological plausibility. Future studies should evaluate the effect and safety of weight loss 308 
during pregnancy in severely obese women.  309 
 Gestational weight gain guidelines are used in several Western countries for preconception 310 
counseling. Gestational weight gain outside the ranges established in this study and outside the IOM 311 
ranges was associated with adverse outcomes. The ranges developed in this study classified fewer women 312 
as having suboptimal weight gain compared to the IOM classification. However, the discriminative 313 
performance, as indicated by AUC, was very weak for both classifications. This suggests that the use of 314 
gestational weight gain guidelines may need to be reconsidered for individual prediction of the risk of 315 
adverse outcomes. Further research needs to assess whether optimal weight gain ranges combined with 316 
other maternal and fetal pregnancy characteristics are useful for prediction of adverse outcomes.  317 
 Findings from this study suggest that pre-pregnancy weight might be a more important target for 318 
interventions than gestational weight gain. Previous intervention studies of dietary and physical activity 319 
for pregnant women have not shown an effect on pregnancy outcomes.
23-26 
Based on current evidence, 320 
future clinical trials designed to reduce weight-related maternal and infant adverse outcomes should focus 321 
on maternal weight before or at the start of pregnancy.  322 
 323 
Limitations 324 
This study has several limitations. First, not all cohorts invited were able to participate in current 325 
analyses. Second, analyses did not measure changes in associations of gestational weight gain with 326 
adverse outcomes over time. Results may be biased, if the associations of gestational weight gain with 327 
adverse outcomes changed over time. Third, data on pre-pregnancy weight was mainly self-reported, and 328 
latest weight during pregnancy was either self-reported or measured. This may have led to 329 
misclassification of gestational weight gain. Fourth, the composite outcome ‘any adverse outcome’ might 330 
have been misclassified as a result of some missing data for adverse individual outcomes. Fifth, all 331 
outcomes were considered equally important and analyses did not account for differences in outcome 332 
severity. Sixth, caesarean section may be due to many factors and may not be an appropriate outcome for 333 
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studying associations of weight change with adverse maternal outcomes. 
7
 Seventh, information on still 334 
birth was not available. Eight, optimal weight gain was defined as a protective association with the risk of 335 
any adverse outcome, reflecting the best outcome possible and limiting the number of participants 336 
incorrectly classified as having adequate weight gain. The ranges would be slightly broader if optimal 337 
weight gain was defined as no increased risk of adverse outcomes, which includes both a protective 338 
association and null-association. Ninth, analyses were not adjusted for multiple testing. Tenth, as a result 339 
of limited sample sizes for underweight and severely obese women, heterogeneity was not assessed. 340 
Eleventh, based on the cohort profiles of all included cohorts, about 1% of women were included more 341 
than once for multiple pregnancies. Twelfth, for some outcomes, discriminative performance in the 342 
validation sample was lower than in the main sample, potentially resulting from overfitting of the models 343 
in the main sample.  344 
 345 
CONCLUSIONS 346 
In this meta-analysis of pooled individual participant data from 25 cohort studies, the risk of adverse 347 
maternal and infant outcomes varied by gestational weight gain and across the range of pre-pregnancy 348 
weights. The estimates of optimal gestational weight gain may inform prenatal counseling, although the 349 
optimal weight gain ranges had limited predictive value for the adverse outcomes assessed.   350 
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Table 1. Characteristics of the study population.
 a,b
  700 
 
Total group Underweight Normal weight Overweight Obesity grade 1 Obesity grade 2 Obesity grade 3 
  (<18.5 kg/m
2
) 
(18.5-24.9 
kg/m
2
) 
(25.0-29.9 
kg/m
2
) 
(30.0-34.9 
kg/m
2
) 
(35.0-39.9 
kg/m
2
) 
(≥40.0 kg/m2) 
 
n= 196670 n =7809 n= 133788 n=38828 n=11992 n=3284 n=969 
Pre-pregnancy body mass index, 
median (Q1, Q3)
b
 
22.7 (20.8, 25.5) 17.9 (17.4, 18.3) 21.8 (20.5, 23.2) 26.8 (25.8, 28.0) 31.8 (30.8, 33.1) 36.7 (35.8, 38) 41.8 (40.8, 43.4) 
Total gestational weight gain (kg)        
Median (Q1, Q3) 14.0 (11.0, 18.0) 14.0 (11.0, 17.0) 14.4 (11.6, 18.0) 14.0 (10.0, 18.0) 11.0 (7.0, 16.0) 9.0 (4.5, 13.7) 7.0 (2.0, 12.0) 
P2.5, P97.5 4.0, 27.0 6.0, 26.0 6.0, 27.0 2.3, 28.0 0.0, 27.0 -2.4, 25.0 -6.0, 25.0 
Maternal age (years), median (Q1, Q3) 30.0 (27.0, 33.0) 29.0 (25.1, 32.0) 30.0 (27.0, 33.0) 30.0 (27.0, 33.3) 30.0 (27.0, 33.0) 30.0 (27.0, 33.3) 30 (27.0, 33.1) 
Education
c 
       
Low, n (%) 42192 (21.9) 1756 (23.0) 25241 (19.2) 9802 (25.7) 3848 (32.8) 1166 (36.5) 379 (40.7) 
Medium, n (%) 78924 (40.9) 3109 (40.7) 52394 (39.9) 16533 (43.4) 5101 (43.5) 1378 (43.2) 409 (43.9) 
High, n (%) 71819 (37.2) 2780 (36.4) 53724 (40.9) 11736 (30.8) 2786 (23.7) 649 (20.3) 144 (15.5) 
Country        
Norway, n (%) 74507 (37.9) 2154 (27.6) 49388 (36.9) 16224 (41.8) 5013 (41.8) 1360 (41.4) 368 (38.0) 
Denmark, n (%) 60963 (31.0) 2583 (33.1) 41344 (30.9) 11930 (30.7) 3762 (31.4) 1024 (31.2) 320 (33.0) 
The Netherlands, n (%) 14861 (7.6) 531 (6.8) 10329 (7.7) 2841 (7.3) 860 (7.2) 235 (7.2) 65 (6.7) 
United Kingdom, n (%) 12610 (6.4) 521 (6.7) 8948 (6.7) 2232 (5.7) 659 (5.5) 191 (5.8) 59 (6.1) 
Portugal, n (%) 7220 (3.7) 293 (3.8) 4783 (3.6) 1525 (3.9) 454 (3.8) 129 (3.9) 36 (3.7) 
Italy, n (%) 5307 (2.7) 428 (5.5) 3893 (2.9) 725 (1.9) 209 (1.7) 50 (1.5) 2 (0.2) 
Germany, n (%) 5099 (2.6) 269 (3.4) 3889 (2.9) 699 (1.8) 183 (1.5) 46 (1.4) 13 (1.3) 
Ukraine, n (%) 3261 (1.7) 303 (3.9) 2360 (1.8) 479 (1.2) 102 (0.9) 16 (0.5) 1 (0.1) 
Greece, n (%) 2872 (1.5) 163 (2.1) 2088 (1.6) 463 (1.2) 118 (1.0) 33 (1.0) 7 (0.7) 
Spain, n (%) 1933 (1.0) 89 (1.1) 1351 (1.0) 344 (0.9) 99 (0.8) 36 (1.1) 14 (1.4) 
United States, n (%) 2021 (1.0) 78 (1.0) 1192 (0.9) 440 (1.1) 195 (1.6) 74 (2.3) 42 (4.3) 
Poland, n (%) 1702 (0.9) 163 (2.1) 1299 (1.0) 191 (0.5) 41 (0.3) 7 (0.2) 1 (0.1) 
Finland, n (%) 1406 (0.7) 39 (0.5) 945 (0.7) 254 (0.7) 119 (1.0) 31 (0.9) 18 (1.9) 
Slovakia, n (%) 983 (0.5) 119 (1.5) 681 (0.5) 130 (0.3) 44 (0.4) 9 (0.3) 0 (0.0) 
Canada, n (%) 844 (0.4) 37 (0.5) 494 (0.4) 166 (0.4) 86 (0.7) 38 (1.2) 23 (2.4) 
a Values are median (Q1, Q3), median (P2.5, P97.5) or n (valid %).  701 
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b Body mass index is calculated as weight in kilograms divided by height in meters squared and is categorized into underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), obesity grade 1 702 
(30.0-34.9 kg/m2), obesity grade 2 (35.0-39.9 kg/m2), and obesity grade 3 (≥40.0 kg/m2). 703 
c Education level was based on cohort-specific criteria. Each cohort used their own country-specific criteria to define low, medium and high educational level. These 3 categories were subsequently used in the meta-analysis.  704 
  705 
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Table 1. Characteristics of the study population (continued).
 a,b
  706 
 
Total group Underweight Normal weight Overweight Obesity grade 1 Obesity grade 2 Obesity grade 3 
  (<18.5 kg/m
2
) 
(18.5-24.9 
kg/m
2
) 
(25.0-29.9 
kg/m
2
) 
(30.0-34.9 
kg/m
2
) 
(35.0-39.9 
kg/m
2
) 
(≥40.0 kg/m2) 
 
n= 196670 n =7809 n= 133788 n=38828 n=11992 n=3284 n=969 
Gestational hypertension, n (%)
c 
6683 (3.9) 151 (2.2) 3583 (3.0) 1776 (5.2) 807 (7.8) 284 (10.3) 82 (10.5) 
Pre-eclampsia, n (%)
d 
5996 (3.5) 112 (1.7) 3067 (2.6) 1637 (4.8) 781 (7.6) 287 (10.4) 112 (13.9) 
Gestational diabetes, n (%)
e 
2946 (1.6) 57 (0.8) 1407 (1.1) 818 (2.2) 420 (3.6) 183 (5.8) 61 (6.6) 
Caesarean section, n (%) 29567 (15.8) 927 (12.6) 17825 (14.1) 6944 (18.7) 2685 (23.3) 882 (27.8) 304 (32.7) 
Preterm birth, n (%)
f 
8250 (4.4) 383 (5.3) 5314 (4.2) 1664 (4.4) 643 (5.5) 177 (5.5) 69 (7.2) 
Small size-for-gestational-age, n (%)
g 
19030 (10.0) 1336 (17.9) 13527 (10.5) 2963 (7.8) 900 (7.7) 224 (7.0) 80 (8.5) 
Large size-for-gestational-age, n (%)
h 
2542 (10.0) 256 (3.4) 10789 (8.4) 5099 (13.5) 1995 (17.0) 649 (20.3) 217 (23.0) 
Childhood underweight, n (%)
i 
2542 (2.0) 196 (4.2) 1865 (2.2) 367 (1.5) 88 (1.2) 20 (1.0) 6 (1.1) 
Childhood overweight, n (%)
j 
21718 (17.2) 348 (7.5) 12263 (14.2) 5814 (23.4) 2328 (31.6) 722 (37.0) 243 (43.2) 
Any adverse outcome, n (%)
k 
73161 (37.2) 2706 (34.7) 45687 (34.1) 16292 (42.0) 6019 (50.2) 1865 (56.8) 592 (61.1) 
a Values are median (Q1, Q3), median (P2.5, P97.5) or n (valid %).  707 
b Body mass index is calculated as weight in kilograms divided by height in meters squared and is categorized into underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), obesity grade 1 708 
(30.0-34.9 kg/m2), obesity grade 2 (35.0-39.9 kg/m2), and obesity grade 3 (≥40.0 kg/m2). 709 
c Gestational hypertension is defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg after 20 weeks of gestation in previously normotensive women.  710 
d Pre-eclampsia is defined as gestational hypertension plus proteinuria.  711 
e Gestational diabetes is defined as either a random glucose level >11.0 mmol/L, a fasting glucose level ≥7.0 mmol/L or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test 712 
(glucose level >7.8 mmol/L after glucose intake).  713 
f  Preterm birth is defined as gestational age at birth <37 weeks.  714 
g Small size-for-gestational-age at birth is defined as sex- and gestational age adjusted birth weight <10th percentile.  715 
h Large size-for-gestational-age at birth is defined as sex- and gestational age adjusted birth >90th percentile.  716 
i Childhood underweight at the highest age available for each child (median (Q1, Q3): 84.9 (61.9, 95.9) months) is defined as sex- and age adjusted standard deviation scores (SDS) <-2.0 SDS for children of 2-5 years of age, 717 
and <-2.0 SDS for children of >5 years. 718 
j Childhood overweight at the highest age available for each child (median (Q1, Q3): 84.9 (61.9, 95.9) months) is defined as sex- and age adjusted standard deviation scores (SDS) >2.0 SDS for children of 2-5 years of age, 719 
and >1.0 SDS for children of >5 years. 720 
k Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large size-for-gestational-age 721 
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FIGURE LEGENDS 722 
Figure 1. Heatmap showing absolute risks of any adverse maternal and infant outcome across the 723 
full ranges of maternal body mass index and gestational weight gain. 724 
Values represent the absolute risks of any adverse maternal and infant outcome (left figure) and the percentages of participants (right figure) for 725 
each combination of body mass index and gestational weight gain. Absolute risks were calculated as (n ( any outcome) / n (body mass index and 726 
gestational weight gain category))*100. The percentages of participants are the number of participants in each cell as a percentage of the total 727 
study sample (n=196670). Participants in the extreme categories of pre-pregnancy BMI and gestational weight gain had values beyond the most 728 
extreme labeled tick marks. Body mass index is calculated as weight in kilograms divided by height in meters squared. Any adverse outcome 729 
includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, preterm birth, small size-for-gestational-age, and large 730 
size-for-gestational-age. Gestational hypertension is defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg 731 
after 20 weeks of gestation in previously normotensive women. Pre-eclampsia is defined as gestational hypertension plus proteinuria. Gestational 732 
diabetes is defined as either a random glucose level >11.0 mmol/L, a fasting glucose level ≥7.0 mmol/L or a fasting glucose level between 6.1 733 
and 6.9 mmol/L with a subsequent abnormal glucose tolerance test (glucose level >7.8 mmol/L after glucose intake). Preterm birth is defined as 734 
gestational age at birth <37 weeks. Small and large size-for-gestational-age at birth are defined as sex- and gestational age adjusted birth weight 735 
<10th percentile and >90th percentile, respectively.  736 
Figure 2. Absolute risks of adverse maternal and infant outcomes across the full range of 737 
gestational weight gain by clinical maternal body mass index group.  738 
The symbols represent the absolute risks of adverse maternal and infant outcomes (absolute risks) within each gestational weight gain category 739 
for women with (A) underweight, (B) normal weight, (C) overweight, (D) obesity grade 1, (E) obesity grade 2 and (F) obesity grade 3. The 740 
symbols represent the mean for all participants in each gestational weight gain category. The percentages below each of the figures represent the 741 
number of participants in that gestational weight gain category as a percentage of all participants within that BMI category. Participants in the 742 
extreme categories of gestational weight gain had values beyond the most extreme labeled tick marks. Absolute risks were calculated as (n 743 
(outcome) / n (gestational weight gain category within BMI group))*100. Body mass index is calculated as weight in kilograms divided by height 744 
in meters squared. Maternal body mass index is categorized into underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-745 
29.9 kg/m2), obesity grade 1 (30.0-34.9 kg/m2), obesity grade 2 (35.0-39.9 kg/m2), and obesity grade 3 (≥40.0 kg/m2). Gestational hypertension is 746 
defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg after 20 weeks of gestation in previously normotensive 747 
women. Pre-eclampsia is defined as gestational hypertension plus proteinuria. Gestational diabetes is defined as either a random glucose level 748 
>11.0 mmol/L, a fasting glucose level ≥7.0 mmol/L or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose 749 
tolerance test (glucose level >7.8 mmol/L after glucose intake). Preterm birth is defined as gestational age at birth <37 weeks. Small and large 750 
size-for-gestational-age at birth are defined as sex- and gestational age adjusted birth weight <10th percentile and >90th percentile, respectively. 751 
Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes , caesarean section, preterm birth, small size-for-752 
gestational-age, and large size-for-gestational-age. Odds ratios for the risk of any adverse outcome per SD increase in maternal pre-pregnancy 753 
BMI and gestational weight gain were 1.28 (95% CI: 1.27, 1.29) and 1.04 (95% CI: 1.03, 1.05), respectively. P-value for comparison: <0.001. 754 
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eTable 7 in Supplement shows the number of cases of each outcome and the total number of participants in each gestational weight gain 755 
category.  756 
Figure 3. Associations of gestational weight gain categories with any adverse outcome per maternal 757 
clinical body mass index group, used to determine optimal weight gain ranges. 758 
The symbols represent odds ratios (OR) 95% Confidence Intervals (CI)) reflecting the risk of any adverse outcome per gestational weight gain 759 
category for women with (A) underweight, (B) normal weight, (C) overweight, (D) obesity grade 1, (E) obesity grade 2 and (F) obesity grade 3, 760 
as compared to all other gestational weight gain categories in that specific clinical maternal body mass index group. The symbols represent the 761 
mean for all participants in each gestational weight gain category. The percentages below each of the figures represent the number of participants 762 
in that gestational weight gain category as a percentage of all participants within that BMI category. Participants in the extreme categories of 763 
gestational weight gain had values beyond the most extreme labeled tick marks. The ORs are presented on a log scale. Body mass index is 764 
calculated as weight in kilograms divided by height in meters squared. Maternal body mass index is categorized into underweight (<18.5 kg/m2), 765 
normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), obesity grade 1 (30.0-34.9 kg/m2), obesity grade 2 (35.0-39.9 kg/m2), and 766 
obesity grade 3 (≥40.0 kg/m2). Any adverse outcome includes pre-eclampsia, gestational hypertension, gestational diabetes, caesarean section, 767 
preterm birth, small size-for-gestational-age, and large size-for-gestational-age. Gestational hypertension is defined as systolic blood pressure 768 
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg after 20 weeks of gestation in previously normotensive women. Pre-eclampsia is defined 769 
as gestational hypertension plus proteinuria. Gestational diabetes is defined as either a random glucose level >11.0 mmol/L, a fasting glucose 770 
level ≥7.0 mmol/L or a fasting glucose level between 6.1 and 6.9 mmol/L with a subsequent abnormal glucose tolerance test (glucose level >7.8 771 
mmol/L after glucose intake). Preterm birth is defined as gestational age at birth <37 weeks. Small and large size-for-gestational-age at birth are 772 
defined as sex- and gestational age adjusted birth weight <10th percentile and >90th percentile, respectively. For the ranges defined in this study , 773 
a statistically significant OR lower than 1 for a gestational weight gain category was considered optimal weight gain. If a non-significant 774 
association (either with an OR above or below or exactly one) for a weight gain category was surrounded by two significant estimates with an OR 775 
below 1, that weight gain category was included in the optimal weight gain range. The red area represents the optimal weight gain range 776 
according to the current analysis, the grey area represents the weight gain ranges as recommended by US Institute of Medicine (IOM). eTable 7 777 
in Supplement shows the number of cases of each any adverse outcome and the total number of participants in each gestational weight gain 778 
category. eFigure 5 in Supplement shows the optimal gestational weight gain ranges based on a protective associations only. 779 
  780 
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